การวิเคราะห์ผลิตภัณฑ์แบบไม่บังคับ
เมื่อคุณอนุญาต เราจะใช้การวิเคราะห์แบบจำกัดที่คำนึงถึงความเป็นส่วนตัวเพื่อดูว่าเส้นทางการวิจัยใดได้ผล เราไม่ใช้ตัวติดตามโฆษณาหรือการบันทึกเซสชัน คุณเปลี่ยนตัวเลือกนี้ได้ในการตั้งค่า อ่าน นโยบายความเป็นส่วนตัว.
Accelerated international expansion of novel monoclonal antibody pain therapies (Lenivia and Portela) combined with a rich late-stage pipeline of multiple potential blockbuster therapies across kidney disease, oncology, and cardiology.
Operating margin drops below 34.5% of revenue over a trailing 12-month period.
Zoetis is rated Buy with Fair value of $95.48, offering 19.9% upside from $79.62 (as of 2026-10-21) as market sentiment overreacts to temporary U.S. dermatology competition and clinic visit declines.
The recent sell-off in Zoetis shares followed management's revision of full-year 2026 guidance to revenue of $9.12B to $9.32B (organic contraction of 1% to 3%) and adjusted diluted EPS of $6.15 to $6.25. This reset reflects an 11% decline in Q2 U.S. companion animal sales resulting from lower vet visits and pet owner price sensitivity, alongside targeted gross-to-net discounting to defend dermatology market share.
However, the underlying earnings power and cash generation of the business remain intact. In FY2025, Zoetis produced $2,904M in operating cash flow and $2,283M in free cash flow on $9,467M of revenue, generating operating margins of 37.84%. Free cash flow conversion exceeds 85%, enabling robust share repurchases that reduced diluted share count from 443.8M in FY2025 to 413.2M.367
With international operations growing 8% in Q2 and livestock surging 23% in the U.S., portfolio diversification provides a strong operational buffer. Trading at 11.99x forward earnings, Zoetis trades at a discount to diversified healthcare peers like BIIB at 14.65x and GEHC at 12.98x, presenting a compelling accumulation opportunity.34
Zoetis trades at 11.99x forward earnings, well below its historical premium and below diversified peers BIIB at 14.65x and GEHC at 12.98x.34
In FY2025, Zoetis converted $2,673M of net income into $2,283M of free cash flow, funding share repurchases that reduced share count to 413.2M.367
International companion animal revenue expanded 8% in Q2 2026, bolstered by European and Canadian rollouts of long-acting monoclonal antibody therapies Lenivia and Portela.
Maintain Buy rating. At $79.62 vs Fair value of $95.48, shares offer an attractive entry point supported by a Narrow economic moat, 85%+ cash conversion (free cash flow relative to net income), and global diversification.3
Zoetis Inc. is the world leader in animal health, discovering, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, and biopharmaceuticals for companion animals (dogs, cats, and horses) and livestock (cattle, swine, poultry, fish, and sheep).
The company operates across two commercial reporting segments: the United States, which contributed $5,097M in FY2025 revenue, and International, which contributed $4,254M. Commercial distribution relies on veterinary clinic relationships, direct sales teams, and veterinary distributors.
In a compounding downside event, U.S. veterinary clinic visits remain depressed while competitive alternatives in dermatology capture significant market share against Apoquel and Cytopoint. Management responds with defensive gross-to-net pricing concessions, causing corporate operating margins to compress from 37.84% in FY2025 to 34.5%. Concurrently, U.S. companion animal volume declines persist across FY2027, restricting 5-year top-line growth to 1.5% and reducing annual operating cash flow generation below $2.4B. Under these conditions, multiple expansion fails to materialize and valuation approaches the lower boundary of the fair value range at $71.42.
In the Bear scenario, competitive entrants capture meaningful market share in canine dermatology, forcing permanent gross-to-net rebates that depress operating margins. U.S. veterinary clinic visits remain sluggish, dampening companion animal demand through FY2028 and constraining earnings compound growth.
Management acknowledged new competitive entry in U.S. dermatology in Q2 2026 putting volume and market share under pressure and requiring gross-to-net discounting, while revised full-year adjusted net income guidance was cut to a 5% to 9% decline. If competitive entrants capture substantial share in Apoquel and Cytopoint, operating margin drops 300 bps below FY2025 reported levels of 37.84%.35
ห้าพัฒนาการที่อาจทำให้กรณีการลงทุนของเราอ่อนแอลง
Indicates structural volume erosion and clinic visit decline rather than transitory destocking, impairing core companion animal revenue recovery.
ปัจจุบัน:-11% in Q2 2026
แจ้งเตือนหากSustained organic contraction worse than -5% through FY2027
Zoetis possesses a Narrow economic moat anchored by its comprehensive animal health product portfolio, global commercial distribution reach, and deep clinical integration with veterinary practitioners. Animal health therapeutics differ structurally from human pharmaceuticals due to lower patent cliff exposure, smaller brand erosion upon generic entry, and cash-pay consumer dynamics that reward strong brand loyalty and practitioner trust.
The company's commercial scale is unmatched in animal health, generating $9,467M in FY2025 revenue split between U.S. ($5,097M) and International ($4,254M). Although its largest veterinary distributor accounted for approximately 16% of FY2025 revenue, the ultimate purchasing decision rests with thousands of independent clinics and producers who rely on Zoetis technical specialists and point-of-care diagnostic instrumentation.
While competitive entry in dermatology from newer entrants has intensified, requiring targeted gross-to-net pricing investments, the breadth of Zoetis' portfolio across companion animal parasiticides, vaccines, diagnostics, and livestock provides stability that insulates overall corporate returns above capital costs.
Zoetis generated $3,597M in operating income and $2,283M in free cash flow on $9,467M of revenue in FY2025. With a computed WACC of 7.76% and cost of equity of 8.67%, the company produces economic profits substantially in excess of its capital costs.2367
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($95.48). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $2.3B after modeled reinvestment of $409.0M, with terminal value at 81.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
In the Bull scenario, veterinary clinic foot traffic rebounds swiftly while international uptake of novel pain monoclonal antibodies Lenivia and Portela exceeds expectations. Dermatology pricing remains resilient as veterinary switching barriers limit competitor share gains. Operating margins expand through operating leverage, and active share repurchases drive sustained compound EPS growth annually.
Demonstrates that international growth and operational cost controls are successfully neutralizing domestic dermatology competition and clinic visit declines.
Confirms that management's revised 2026 outlook is realistic and that earnings power remains on track for recovery toward $6.52 per share in FY2027.
Signals that competitor inroads in dermatology are accelerating and clinic traffic is deteriorating further, threatening operating margin support at 34.5%.
Zoetis exhibits high earnings quality supported by strong cash conversion. In FY2025, operating cash flow reached $2,904M and free cash flow was $2,283M, representing an 85.4% conversion rate from reported net income of $2,673M. Stock-based compensation of $83M represents less than 1% of revenue. Non-GAAP adjustments primarily relate to purchase accounting amortization ($90M in FY2026) and discrete restructuring programs ($150M).67
Following the Q2 2026 earnings release, consensus estimates experienced downward revisions. FY2026 consensus EPS fell from $6.87 pre-event to $6.21, while FY2026 revenue consensus adjusted from $9.74B to $9.25B. FY2027 consensus EPS adjusted from $7.39 to $6.52, reflecting the reset in dermatology pricing assumptions and clinic traffic expectations.1
Determines whether pet owner price elasticity and veterinary visit contraction are stabilizing.
Crucial to verify whether Apoquel and Cytopoint retain market leadership against new entrants.
Cash generation is exceptionally strong. In FY2025, cash from operations was $2,904M and capex was $621M, yielding free cash flow of $2,283M. Free cash flow conversion stood at 85.4% of reported net income ($2,673M). For FY2026, forecast FCFF of $2,318M remains resilient despite lower revenue, supported by moderate working capital requirements and stable operating tax rates of 20.36%.267
Zoetis demonstrates disciplined capital allocation focused on organic R&D, capacity investment, and aggressive cash return. In FY2025, was $621M (6.6% of ), supporting next-generation biologics capacity. Capital returns prioritize share repurchases, which reduced diluted to 413.2M by October 2026 from 443.8M diluted average shares in FY2025. Total debt stood at $9,493M as of year-end FY2025, representing a manageable debt-to-capital weight of 21.95%. The board declared a $0.53/share dividend in Q4 2026, maintaining an annualized $2.12 payout.
Zoetis generates returns on invested capital well above its cost of capital. With an operating margin of 37.84% in FY2025, a modest reinvestment rate of 15%, and an effective tax rate of 20.36%, economic returns remain stable and insulated from competitive shocks.
ROIC exceeds WACC of 7.76% by over 1,000 basis points.
FY2025 operating income reached $3,597M on $9,467M revenue (37.84% margin), compared to industry average operating margin of 29.5%.
| รายได้ | US$2,468,000,000 |
|---|---|
| ต้นทุนรายได้ | US$673,000,000 |
| กำไรขั้นต้น | US$1,795,000,000 |
| ค่าใช้จ่ายในการดำเนินงาน | US$858,000,000 |
| กำไรจากการดำเนินงาน | US$937,000,000 |
| รายการที่ไม่ใช่การดำเนินงานและภาษี | -US$246,000,000 |
| กำไรสุทธิ | US$691,000,000 |
| สินทรัพย์รวม | US$15,467,000,000 |
|---|---|
| เงินสด | US$2,312,000,000 |
| สินทรัพย์หมุนเวียน | US$6,768,000,000 |
| หนี้สินรวม | US$12,136,000,000 |
| หนี้สินหมุนเวียน | US$2,235,000,000 |
| ส่วนของผู้ถือหุ้น | US$3,331,000,000 |
| กำไรสุทธิ | US$2,673,000,000 |
|---|---|
| กระแสเงินสดรับจากการดำเนินงาน | US$3,243,000,000 |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | US$487,000,000 |
| ค่าตอบแทนที่จ่ายเป็นหุ้น | US$83,000,000 |
| กระแสเงินสดจากการดำเนินงาน | US$2,904,000,000 |
| กระแสเงินสดจ่ายจากการดำเนินงาน | US$339,000,000 |
| เงินสดที่มีอยู่ | US$4,930,000,000 |
| เงินสดต้นงวด | US$1,987,000,000 |
| ผลกระทบจากอัตราแลกเปลี่ยน | US$39,000,000 |
| เงินสดจ่ายจากการลงทุน | US$748,000,000 |
| Capex | US$621,000,000 |
| กิจกรรมลงทุนอื่น | US$127,000,000 |
| เงินสดจ่ายจากการจัดหาเงิน | US$1,870,000,000 |
| การออกหนี้สุทธิ | US$2,498,000,000 |
| การซื้อหุ้นคืน | US$3,235,000,000 |
| เงินปันผลที่จ่าย | US$889,000,000 |
| กิจกรรมจัดหาเงินอื่น | US$244,000,000 |
| เงินสดปลายงวด | US$2,312,000,000 |
| กระแสเงินสดจากการลงทุน | -US$748,000,000 |
| กระแสเงินสดจากการจัดหาเงิน | -US$1,870,000,000 |
ข้อมูลการเงิน ณ จุดเวลาที่ใช้ในการวิเคราะห์วันที่ 2026-10-22
| ช่วงเวลา | รายได้ | EBITDA | กำไรสุทธิ | กระแสเงินสดจากการดำเนินงาน | กระแสเงินสดอิสระ | Capex | ค่าเสื่อมราคาและค่าตัดจำหน่าย | ค่าตอบแทนที่จ่ายเป็นหุ้น | การซื้อหุ้นคืน | เงินปันผลที่จ่าย | การออกหนี้สุทธิ | กระแสเงินสดจากการลงทุน | กระแสเงินสดจากการจัดหาเงิน | เงินสดต้นงวด | เงินสดปลายงวด | เงินสดและเงินลงทุน | หนี้สินรวม | อัตรากำไรจากการดำเนินงาน | ROIC | WACC | ส่วนต่าง ROIC−WACC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$4.9B | US$1.6B | US$821M | US$713M | US$497M | US$216M | US$240M | US$37M | US$300M | US$188M | — | -US$214M | -US$903M | — | US$727M | US$727M | US$4.5B | 28.7% | — | 5.5% | — |
| 2017-12-31 | US$5.3B | US$1.9B | US$864M | US$1.3B | US$1.1B | US$224M | US$242M | US$44M | US$500M | US$206M | — | -US$270M | -US$251M | US$727M | US$1.6B | US$1.6B | US$5B | 32.5% | — | 5.4% | — |
| 2018-12-31 | US$5.8B | US$2.2B | US$1.4B | US$1.8B | US$1.5B | US$338M | US$308M | US$53M | US$698M | US$243M | — | -US$2.3B | US$533M | US$1.6B | US$1.6B | US$1.7B | US$6.5B | 32.3% | — | 5.7% | — |
| 2019-12-31 | US$6.3B | US$2.5B | US$1.5B | US$1.8B | US$1.3B | US$460M | US$412M | US$67M | US$626M | US$314M | — | -US$504M | -US$951M | US$1.6B | US$1.9B | US$1.9B | US$6.6B | 32.2% | — | 5.1% | — |
| 2020-12-31 | US$6.7B | US$2.7B | US$1.6B | US$2.1B | US$1.7B | US$453M | US$441M | US$59M | US$250M | US$380M | — | -US$572M | US$123M | US$1.9B | US$3.6B | US$3.6B | US$7.4B | 34.0% | — | 4.0% | — |
| 2021-12-31 | US$7.8B | US$3.2B | US$2B | US$2.2B | US$1.7B | US$477M | US$448M | US$58M | US$743M | US$474M | — | -US$458M | -US$1.9B | US$3.6B | US$3.5B | US$3.5B | US$6.7B | 36.0% | — | 4.8% | — |
| 2022-12-31 | US$8.1B | US$3.4B | US$2.1B | US$1.9B | US$1.3B | US$586M | US$465M | US$62M | US$1.6B | US$611M | US$1.4B | -US$883M | -US$904M | US$3.5B | US$3.6B | US$3.6B | US$8.1B | 36.2% | — | 7.3% | — |
| 2023-12-31 | US$8.5B | US$3.7B | US$2.3B | US$2.4B | US$1.6B | US$732M | US$491M | US$60M | US$1.1B | US$692M | -US$1.3B | -US$777M | -US$3.1B | US$3.6B | US$2B | US$2B | US$6.8B | 35.9% | — | 7.5% | — |
| 2024-12-31 | US$9.3B | US$3.9B | US$2.5B | US$3B | US$2.3B | US$655M | US$497M | US$74M | US$1.9B | US$786M | -US$3M | -US$315M | -US$2.7B | US$2B | US$2B | US$2B | US$6.7B | 36.6% | — | 8.0% | — |
| 2025-12-31 | US$9.5B | US$4.1B | US$2.7B | US$2.9B | US$2.3B | US$621M | US$487M | US$83M | US$3.2B | US$889M | US$2.5B | -US$748M | -US$1.9B | US$2B | US$2.3B | US$2.3B | US$9.5B | 38.0% | — | 7.4% | — |
Zoetis Inc. (ZTS) trades at 12.0x forward earnings against a peer median of 16.6x. Its EV/EBITDA of 10.0x compares with a peer median of 14.6x. The comparison uses 4 peers: DexCom Inc., GE HealthCare Technologies Inc., ResMed Inc. and Biogen Inc., as of 2026-10-21.
Industry capex-to-revenue benchmark is 1.1% and industry capex-to-depreciation stands at 0.8x. Zoetis maintains higher capital intensity to support proprietary biologics, investing $621M in capex (6.6% of revenue) in FY2025.7
The long-term industry expansion is propelled by pet humanization, increasing medicalization rates in emerging markets, preventative veterinary care, and rising global animal protein demand requiring livestock disease prevention.
Downside industry conditions stem from pet owner price sensitivity, cumulative veterinary inflation over recent years, and discretionary visit deferrals that pressure volume across companion animal clinics.
Zoetis holds the #1 market share globally in animal health, with leading positions across major companion animal categories (parasiticides, dermatology, pain) and livestock species (cattle, poultry, swine). Its balanced revenue split between the U.S. ($5,097M) and International ($4,254M) insulates the business against localized market downturns.8
High conviction is supported by Zoetis' Narrow economic moat, dominant global distribution scale, 85%+ FCF conversion, and a cyclically low valuation of 11.99x forward P/E.3
Risk management centers on monitoring competitive prescription dynamics in canine dermatology and tracking veterinary clinic visit indicators. Exposure is capped strictly within recommended allocation limits, with downside protection provided by livestock diversification and recurring parasiticide volume.
Trading at 11.99x forward P/E, Zoetis trades at a sharp discount to peers BIIB at 14.65x and GEHC at 12.98x, while maintaining superior 37%+ operating margins.34
Temporary growth deceleration creates a mispriced entry point into an animal health powerhouse advancing 12+ blockbuster pipeline candidates and expanding internationally.
A $2.12 annualized dividend provides income support, but conservative accounts should hold existing positions until U.S. companion animal volume stabilizes.
Zoetis is rated Buy with Fair value of $95.48, presenting 19.9% upside from $79.62 (as of 2026-10-21).
The market has over-discounted cyclical headwinds in U.S. veterinary clinic visits and dermatology competition, creating an attractive entry multiple of 11.99x forward earnings for a premier compounder with robust free cash flow conversion.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
U.S. companion animal revenue dropped 11% in Q2 2026 due to declining clinic visits and pet owner price sensitivity, compounded by generic competition on Cerenia and Convenia. If veterinary visit contraction persists and volume fails to rebound in FY2027-FY2028, revenue growth lags the base schedule by 500 bps.15
Zoetis trades at a forward P/E of 11.99x, while healthcare peers like BIIB trade at 14.65x and GEHC at 12.98x. If persistent top-line stagnation and patent challenges erode premium compounder status, the exit multiple derates 20% from the modeled 15.0x terminal multiple to 12.0x.34
Reflects permanent gross-to-net promotional discounting to defend canine dermatology share against new entrants.
ปัจจุบัน:37.84% reported in FY2025 / 37.0% FY2026 forecast
แจ้งเตือนหากOperating margin falling below 34.5% of revenue
Demonstrates that operational cost containment is insufficient to offset revenue deceleration and margin degradation.
ปัจจุบัน:FY2026 guidance range of $6.15 to $6.25
แจ้งเตือนหากBelow $6.00 in FY2026 or failing to achieve $6.52 in FY2027
Erosion of the key international growth buffer exposing the consolidated business to unmitigated domestic veterinary headwinds.
ปัจจุบัน:+8% reported (+5% organic operational) in Q2 2026
แจ้งเตือนหากGrowth decelerating below +2% operational
Constrains capital return programs, slowing the pace of share repurchases and muting EPS accretion.
ปัจจุบัน:85.4% in FY2025 ($2,283M FCF / $2,673M net income)
แจ้งเตือนหากConversion rate dropping below 70%
| medium |
| Next 6-18 months |
| Expanding international penetration (+8% Q2 2026 growth) and capturing livestock tailwinds (+23% U.S. livestock growth in Q2 2026). |
| Generic erosion on mature small-molecule brands Cerenia and Convenia. | low | Ongoing | Launching next-generation products (such as Lenivia and Portela) and driving livestock biologicals adoption. |
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows (US$23.71) plus discounted terminal value (US$101) minus signed per current share (US$17.38) equals the US$107 lens value shown above. Negative net debt is , so subtracting it raises value.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Solve for the growth rate that makes the model value equal the report-date share price.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
In the Base scenario, FY2026 revenue reflects the reset guidance range ($9.12B to $9.32B) with EPS of $6.21, before accelerating to 2.51% revenue growth and $6.52 EPS in FY2027. Operating margins normalize to 38.5% by FY2030, while free cash flow generation enables sustained share count reduction of ~1% per year.5
Serves as the primary operational hedge against U.S. market softness.
Provides counter-cyclical margin support driven by cattle economics and poultry vaccine demand.
Essential to drive EPS accretion during period of modest operational revenue growth.
| $9.91B |
| $10.41B |
| $10.93B |
| Revenue growth | -2.3% | 2.5% | 4.5% | 5.0% | 5.0% |
| Operating margin | 37.0% | 37.5% | 38.0% | 38.2% | 38.5% |
| Operating income | $3.42B | $3.56B | $3.77B | $3.98B | $4.21B |
| Tax rate | 20.4% | 20.4% | 20.5% | 20.5% | 20.5% |
| NOPAT | $2.73B | $2.83B | $2.99B | $3.16B | $3.34B |
| Reinvestment | $408.99M | $424.92M | $479.11M | $505.72M | $501.72M |
| Reinvestment rate (of NOPAT) | 15.0% | 15.0% | 16.0% | 16.0% | 15.0% |
| Free cash flow to firm | $2.32B | $2.41B | $2.52B | $2.66B | $2.84B |
| United States revenue | $4.98B | $5.11B | $5.34B | $5.60B | $5.88B |
| International revenue | $4.16B | $4.26B | $4.45B | $4.68B | $4.91B |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
In Q2 2026, International revenue grew 8% (to $1,173M) and U.S. livestock grew 23% (to $222M), offsetting an 11% contraction in U.S. companion animal sales.
Geographic and species diversification insulates Zoetis from localized U.S. veterinary clinic slowdowns.
Diluted share count decreased from 443.8M in FY2025 to 413.2M in October 2026, representing a 6.9% share reduction.
Aggressive buybacks at cyclically compressed multiples amplify future EPS expansion as top-line growth recovers.
| อัตรากำไร |
|---|
| ZTS | Zoetis Inc. | $32.9B | 12.0x | 3.5x | 10.0x | 64.9% | — |
| DXCM | DexCom Inc. | $32.4B | 27.5x | 6.5x | 22.7x | 38.5% | 24.3% |
| GEHC | GE HealthCare Technologies Inc. | $31.9B | 13.0x | 1.5x | 11.3x | 19.4% | 15.0% |
| RMD | ResMed Inc. | $34.5B | 18.5x | 6.1x | 16.6x | 24.3% | 30.9% |
| BIIB | Biogen Inc. | $35.6B | 14.6x | 3.6x | 12.7x | 4.6% | 25.1% |
| negative |
| Inflationary pressures over the past two years have led pet owners to stretch veterinary visit intervals, moderating foot traffic to clinics in the near term. |
| Corporate operating margin falling below 34.5% of revenue |
| Conduct immediate kill scenario review and halt tranche deployment. |
| Full-Year Adjusted Diluted EPS | Falling below $6.15 lower guidance threshold | Review operational execution and adjust 2027 earnings growth trajectory. |
